Last Updated on October 10, 2024 by The Health Master
The US Food and Drug Administration (USFDA) has given final approval to Alembic Pharma’s abbreviated new drug application (ANDA), Desonide Cream, 0.05%.
The ANDA was filed by Aleor Dermaceuticals, which was merged with Alembic, according to a statement from Alembic Pharma.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Desonide Cream, 0.05%, of Padagis.
Desonide cream, 0.05% is a low-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, the statement said.
USFDA gives nod for Diclofenac Sodium topical solution
USFDA gives approval for Venlafaxine ER tablets
USFDA gives nod for Levothyroxine Sodium For Injection
USFDA gives nod for Nifedipine ER tablets
USFDA gives nod for Amphotericin B Liposome Injection
USFDA gives approval for Potassium-deficiency drug
Gujarat sets up new 784 manufacturing units during the last one year
National roundtable on safe Blood Transfusions
USFDA lists Sun Pharma’s Halol unit under ‘Import Alert’
Govt soon to set up Export Promotion Council for Medical Devices
CDSCO Panel gives nod for FDC Tamsulosin + Solifenacin
IPC alert: About Norfloxacin induced skin hyperpigmentation
NPPA releases 4th list of draft ceiling prices for 15 formulations
J&J baby powder sample fails quality test: FDA latest lab report
NPPA releases 3rd list with draft ceiling prices for 43 formulations
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
